A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 5, 2013, Pages 545-556

  Tegenge, Million A ^a   Mitkus, Robert J ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Adjuvants; ASO3; MF59; Pharmacokinetics; Squalene; Vaccine

Indexed keywords

ASO 3; IMMUNOLOGICAL ADJUVANT; MIFAMURTIDE; SQUALENE; UNCLASSIFIED DRUG; VACCINE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DELTOID MUSCLE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG TRANSFORMATION; DRUG TRANSPORT; EMULSION; HUMAN; IMMUNOGENICITY; INJECTION SITE; LYMPH NODE; MOUSE; NONHUMAN; PASSIVE TRANSPORT; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PHYSIOLOGICAALY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

ADIPOSE TISSUE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; EMULSIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; KINETICS; LYMPH NODES; MICE; MODELS, BIOLOGICAL; SQUALENE; TISSUE DISTRIBUTION; VACCINES;

EID: 84885584512     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-013-9328-y     Document Type: Article

References (60)

1. Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12:509-517
2. Levitz SM, Golenbock DT (2012) Beyond empiricism: informing vaccine development through innate immunity research. Cell 148:1284-1292
3. Sette A, Rappuoli R (2010) Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33:530-541
4. Garcon N, Vaughn DW, Didierlaurent AM (2012) Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 11:349-366
5. Gasparini R, Amicizia D, Lai PL, Panatto D (2012) Aflunov((R)): a prepandemic influenza vaccine. Expert Rev Vaccines 11:145-157
6. O'Hagan DT, Rappuoli R, De GE, Tsai T, Del GG (2011) MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 10:447-462
7. O'Hagan DT, Ott GS, De GE, Seubert A (2012) The mechanism of action of MF59: an innately attractive adjuvant formulation. Vaccine 30:4341-4348
8. Cosmetic Ingredient Review (1982) Final report on the safety assessment of squalane and squalene. Int J Toxicol 1:37-56
9. Liu GC, Ahrens EH, Schreibman PH, Crouse JR (1976) Measurement of squalene in human tissues and plasma: validation and application. J Lipid Res 17:38-45
10. Chung H, Kim TW, Kwon M, Kwon IC, Jeong SY (2001) Oil components modulate physical characteristics and function of the natural oil emulsions as drug or gene delivery system. J Control Release 71:339-350
11. Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS (2011) Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 29:9563-9572
12. Fox CB, Barnes VL, Evers T, Chesko JD, Vedvick TS, Coler RN, Reed SG, Baldwin SL (2012) Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy. Influenza Other Respi Viruses. doi: 10.1111/irv.12031
13. Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, Pfleiderer M, Kato A, Cavaleri M, Southern J, Jivapaisarnpong T, Minor P, Griffiths E, Sohn Y, Wood D (2013) A global regulatory science agenda for vaccines. Vaccine 31:B163-B175
14. WHO (2005) WHO guidelines on nonclinical evaluation of vaccines. WHO Technical Report Series No. 927, Annex 1
15. Sun Y, Gruber M, Matsumoto M (2012) Overview of global regulatory toxicology requirements for vaccines and adjuvants. J Pharmacol Toxicol Methods 65:49-57
16. Wolf JJ, Kaplanski CV, Lebron JA (2010) Nonclinical safety assessment of vaccines and adjuvants. Methods Mol Biol 626:29-40
17. Gylling H, Miettinen TA (1994) Postabsorptive metabolism of dietary squalene. Atherosclerosis 106:169-178
18. Tilvis RS, Miettinen TA (1983) Absorption and metabolic fate of dietary 3H-squalene in the rat. Lipids 18:233-238
19. Tilvis RS, Miettinen TA (1982) Fate of intravenously administered squalene in the rat. Biochim Biophys Acta 712:374-381
20. Relas H, Gylling H, Miettinen TA (2001) Fate of intravenously administered squalene and plant sterols in human subjects. J Lipid Res 42:988-994
21. Yamasaki S (1950) On the fate of squalene in the animal body. J Biochem 37:99-104
22. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van HP, van NG (1995) MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6:277-296
23. Dupuis M, McDonald DM, Ott G (1999) Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18:434-439
24. Fox CB (2009) Squalene emulsions for parenteral vaccine and drug delivery. Molecules 14:3286-3312
25. Rippe B, Haraldsson B (1994) Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 74:163-219
26. Sarin H (2010) Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2:14
27. Bollinger JN (1970) Metabolic fate of mineral oil adjuvants using 14C-labeled tracers II. Mannide monooleate. J Pharm Sci 59:1088-1092
28. Kalvodova L (2010) Squalene-based oil-in-water emulsion adjuvants perturb metabolism of neutral lipids and enhance lipid droplet formation. Biochem Biophys Res Commun 393:350-355
29. van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A (1999) Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 5:2918-2924
30. Van den Broeck W, Derore A, Simoens P (2006) Anatomy and nomenclature of murine lymph nodes: descriptive study and nomenclatory standardization in BALB/cAnNCrl mice. J Immunol Methods 312:12-19
31. West DB, Boozer CN, Moody DL, Atkinson RL (1992) Dietary obesity in nine inbred mouse strains. Am J Physiol 262:R1025-R1032
32. International Life Sciences Institute Risk Science Institute (1994) Physiological parameter values For PBPK Models, pp 1-103
33. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67-86
34. Pistilli EE, Bogdanovich S, Garton F, Yang N, Gulbin JP, Conner JD, Anderson BG, Quinn LS, North K, Ahima RS et al (2011) Loss of IL-15 receptor alpha alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles. J Clin Invest 121:3120-3132
35. Swartz MA (2001) The physiology of the lymphatic system. Adv Drug Deliv Rev 50:3-20
36. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484
37. Evans EF, Proctor JD, Fratkin MJ, Velandia J, Wasserman AJ (1975) Blood flow in muscle groups and drug absorption. Clin Pharmacol Ther 17:44-47
38. Potau JM, Bardina X, Ciurana N, Camprubi D, Pastor JF, de Paz F, Barbosa M (2009) Quantitative analysis of the deltoid and rotator cuff muscles in humans and great apes. Int J Primatol 30:697-708
39. Poland GA, Borrud A, Jacobson RM, McDermott K, Wollan PC, Brakke D, Charboneau JW (1997) Determination of deltoid fat pad thickness. Implications for needle length in adult immunization. JAMA 277:1709-1711
40. Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Howells GP, Tipton IH (1992) Report of the Task Group on Reference Man. Pergamon Press plc, New York
41. Poulin P, Haddad S (2012) Advancing prediction of tissue distribution and volume of distribution of highly lipophilic compounds from a simplified tissue-composition-based model as a mechanistic animal alternative method. J Pharm Sci 101:2250-2261
42. Angel A, Bray GA (1979) Synthesis of fatty acids and cholesterol by liver, adipose tissue and intestinal mucosa from obese and control patients. Eur J Clin Invest 9:355-362
43. Miettinen TA, Tilvis RS (1981) Cholesterol synthesis and storage in adipose tissue. Int J Obes 5:613-618
44. Nikkari T, Schreibman PH, Ahrens EH Jr (1974) In vivo studies of sterol and squalene secretion by human skin. J Lipid Res 15:563-573
45. Nicolaides N, Rothman S (1955) The site of sterol and squalene synthesis in the human skin. J Invest Dermatol 24:125-129
46. Urva SR, Yang VC, Balthasar JP (2010) Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci 99:1582-1600
47. Fulco CE, Liverman CT, Sox HC (2000) Gulf War and Health. In: Depleted uranium, sarin, pyridostigmine bromide, vaccines, vol 1. The National Academies Press, Washington
48. Arguedas A, Soley C, Abdelnour A, Sales V, Lindert K, Della CG, Clemens R (2011) Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccine 7:58-66
49. Durando P, Icardi G, Ansaldi F (2010) MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 10:639-651
50. El Sahly H (2010) MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 9:1135-1141
51. Montana M, Verhaeghe P, Ducros C, Terme T, Vanelle P, Rathelot P (2010) Safety review: squalene and thimerosal in vaccines. Therapie 65:533-541
52. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R (2008) Safety of MF59 adjuvant. Vaccine 26:3209-3222
53. Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, Baudner B, Seubert A, De GE (2012) MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol 188:3088-3098
54. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R, De GE (2008) Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105:10501-10506
55. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H et al (2011) Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461-2473
56. Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, van Nest G, Ott G, McDonald DM (1998) Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 186:18-27
57. Valensi JP, Carlson JR, Van Nest GA (1994) Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 153:4029-4039
58. Tilvis R, Kovanen PT, Miettinen TA (1982) Metabolism of squalene in human fat cells. Demonstration of a two-pool system. J Biol Chem 257:10300-10305
59. Gray H (1918) Anatomy of the human body. Philadelphia: Lea & Febiger, Bartleby.com, 2000. www.bartleby.com/107/. Accessed 9 Jan 2012
60. Haschek W, Rousseaux C (1998) Fundamentals of Toxicologic Pathology. Academic Press, San Diego